Shares of Horizon rose nearly 3% in premarket trading Friday. Amgen's stock edged up slightly.Amgen first moved to buy Horizon in December 2022 in an effort to gain access to the latter's rare disease assets, including the thyroid eye disease therapy Tepezza.
In its lawsuit, the FTC said that the deal would allow Amgen to "entrench the monopoly positions" of Horizon's fast-growing medications, including Tepezza, and Krystexxa, a gout medicine.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más: